Olumiant Shortage: What Providers and Prescribers Need to Know in 2026

For rheumatologists, dermatologists, and other prescribers managing patients on Olumiant (baricitinib), understanding the current access landscape is essential for patient care planning. While Olumiant is not listed on the FDA drug shortage database as of early 2026, your patients face real and complex barriers to getting their medication. This guide covers what you need to know — and what you can do to help.

Current FDA Shortage Status

As of early 2026, baricitinib (Olumiant) is not listed on the FDA's drug shortage database. Eli Lilly reports stable manufacturing capacity across all three approved indications: rheumatoid arthritis, alopecia areata, and COVID-19. The supply disruptions seen in 2020–2021 — driven by Emergency Use Authorization demand from hospitalized COVID-19 patients — have resolved. However, your patients' access difficulties are largely systemic, not manufacturing-related.

Why Your Patients Are Still Struggling to Access Olumiant

Baricitinib's limited distribution through specialty pharmacies creates barriers that retail prescriptions don't encounter. The key friction points your patients face include:

Prior authorization (PA) requirements: Virtually all payers require PA for Olumiant. For RA patients, most plans require demonstrated failure of at least one — often two — conventional DMARDs and at least one TNF inhibitor before approving a JAK inhibitor.

Step therapy mandates: Many commercial plans and some Medicare Part D plans require step therapy through cheaper alternatives (methotrexate, hydroxychloroquine, TNF inhibitors) before approving Olumiant — even for patients who have a documented history of intolerance or failure.

Specialty pharmacy designation: Patients must use their insurer's designated specialty pharmacy. A prescription sent to the wrong pharmacy results in either a rejected claim or a full-price dispensing.

Cost barriers: The wholesale acquisition cost for baricitinib 2 mg is approximately $2,767 for a 30-day supply. Patients on specialty tiers may face $100–$500+ monthly copays even with insurance.

Clinical Considerations: Safety Monitoring for Patients on Baricitinib

Olumiant carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Key monitoring considerations:

Screen for latent TB before initiation and monitor for TB signs during therapy

Monitor CBC, LFTs, and lipid panel approximately 12 weeks after initiation and periodically thereafter

Do not initiate if ALC < 500 cells/mm³, ANC < 1000 cells/mm³, or Hgb < 8 g/dL; interrupt therapy if these thresholds are crossed

Assess CV risk before and during therapy — the MACE risk is elevated in patients ≥50 years with ≥1 CV risk factor (especially current or former smokers)

Avoid use with other JAK inhibitors, biologic DMARDs, azathioprine, or cyclosporine

Reduce baricitinib dose to 1 mg/day if co-administered with probenecid (strong OAT3 inhibitor)

Not recommended in patients with eGFR < 60 mL/min/1.73 m²

Strategies to Accelerate Prior Authorization Approval

Your prior authorization team can improve approval rates and speed with these strategies:

Document the step therapy history clearly — list all prior DMARDs and biologics with dates, doses, and reason for failure or discontinuation

For AA patients, document severity using SALT score; for RA patients, include DAS28 or CDAI scores

Use the Olumiant Together program (1-844-658-6426) — they provide PA support and have payer-specific experience

Request peer-to-peer review if an initial PA is denied — a direct conversation with the medical reviewer often reverses denials

Provide bridge samples while PA is pending — Lilly may provide samples for eligible new-start patients

Clinical Alternatives When Olumiant Access Fails

If your patient cannot access Olumiant despite exhausting the above avenues, consider:

RA: Upadacitinib (Rinvoq) — comparable efficacy; JAK1-selective. Or tofacitinib (Xeljanz), particularly if the patient has previously tolerated it.

AA: Ritlecitinib (Litfulo, approved 2023) or deuruxolitinib (Leqselvi, approved 2024) — both FDA-approved for severe AA

RA bridge: Consider short-course corticosteroid bridge while PA is being resolved

How medfinder Can Help Your Patients

When your patients have a prescription in hand but are unable to locate a specialty pharmacy with available Olumiant, medfinder for providers can help. medfinder calls pharmacies in the patient's area to identify which ones can fill the prescription — saving your staff time and getting patients their medication faster. Consider recommending medfinder as part of your practice's medication access workflow.